# Safety And Effectiveness Of Daily Dosing With Sunitinib Or Imatinib In Patients With Gastrointestinal Stromal Tumors

> **NCT00372567** · PHASE3 · TERMINATED · sponsor: **Pfizer** · enrollment: 69 (actual)

## Conditions studied

- Gastrointestinal Stromal Tumor

## Interventions

- **DRUG:** sunitinib malate
- **DRUG:** imatinib mesylate

## Key facts

- **NCT ID:** NCT00372567
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-06
- **Primary completion:** 2009-11
- **Final completion:** 2009-11
- **Target enrollment:** 69 (ACTUAL)
- **Why stopped:** See termination reason in detailed description.
- **Last updated:** 2011-03-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00372567

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00372567, "Safety And Effectiveness Of Daily Dosing With Sunitinib Or Imatinib In Patients With Gastrointestinal Stromal Tumors". Retrieved via AI Analytics 2026-08-03 from https://api.ai-analytics.org/clinical/NCT00372567. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*